SCHEDULE 13G 0001856083 XXXXXXXX LIVE Common Shares, no par value 10/28/2025 0001833141 CYBIN INC. 23256X407 100 King Street West Suite 5600 Toronto, Ontario A6 M5X 1C9 Rule 13d-1(c) Deep Track Capital, LP b DE 0.00 3072250.00 0.00 3072250.00 3072250.00 N 6.09 IA OO Deep Track Biotechnology Master Fund, Ltd. b E9 0.00 3072250.00 0.00 3072250.00 3072250.00 N 6.09 CO David Kroin b X1 0.00 3072250.00 0.00 3072250.00 3072250.00 N 6.09 HC IN CYBIN INC. 100 King Street West, Suite 5600, Toronto, Ontario, M5X IC9 (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (i) Delaware (ii) Cayman Islands (iii) United States Y 3,072,250 6.09% 0 3,072,250 0 3,072,250 Y Y N Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of November 4, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 50,431,381 shares, calculated using 49,894,131 Common Stock outstanding as of October 28, 2025, and 537,250 Warrants that would be converted to Common Stock by the Reporting Person up to the Maximum Percentage. The beneficially owned shares include 537,250 Warrants exercisable to common stock, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of the Warrants, to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Common Stock outstanding immediately after giving effect to such exercise. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 4, 2025 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin Deep Track Capital, LP /s/ David Kroin 11/04/2025 Deep Track Biotechnology Master Fund, Ltd. /s/ David Kroin 11/04/2025 David Kroin /s/ David Kroin 11/04/2025